Comparison of the immune response induced in mice by five commercial vaccines based on recombinant HBsAg from different sources, implications on their therapeutic use
Yadira Lobaina(Centro de Ingeniería Genética y Biotecnología), Julio Aguilar(Centro de Ingeniería Genética y Biotecnología), Enrique V. Iglesias(Sorbonne Université), Gerardo Guillén(Hunan City University), Verena Muzio(Centro de Ingeniería Genética y Biotecnología), Eduardo Pentón(Centro de Ingeniería Genética y Biotecnología), Diane Rodríguez(Fordham University), Laritza Gorovaya(Centro de Ingeniería Genética y Biotecnología), Daymir García(Centro de Ingeniería Genética y Biotecnología)
Biotecnología aplicada
January 1, 2008
Cited by 1
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134